S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q4 2023

Baker Bros Advisors

Period: Q4 2023 Β· Filed: 2024-02-14
View on SEC EDGAR β†—
AUM
$8.79B
Total portfolio value
Positions
84
Reported securities
Top Holding
INCY
25.9% $2.27B
QoQ Changes
+5 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2024-02-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
INCYIncyte Corporation$2.27B25.85%$65.45$116.86+78.5%
25.9%
ONCBeiGene, Ltd.$1.91B21.69%$177.00$297.65+68.2%
21.7%
ACADACADIA Pharmaceuticals Inc.$1.34B15.27%$30.86$25.97-15.8%
15.3%
MDGLMadrigal Pharmaceuticals, Inc.$455.8M5.19%$226.86$528.10+132.8%
5.2%
RYTMRhythm Pharmaceuticals, Inc.$294.1M3.35%$45.13$114.17+153.0%
3.4%
MRTXMirati Therapeutics, Inc.$242.1M2.76%β€”β€”
2.8%
IMCRImmunocore Holdings plc$172.2M1.96%$71.64$32.50-54.6%
2.0%
KYMRKymera Therapeutics, Inc.$152.7M1.74%$25.35$113.51+347.8%
1.7%
RVMDRevolution Medicines, Inc.$147.7M1.68%$28.23$189.24+570.4%
1.7%
Invitae Corporation$131.2M1.49%β€”β€”
1.5%
ABCLAbCellera Biologics Inc.$130.8M1.49%$5.73$8.11+41.5%
1.5%
ROIVRoivant Sciences Ltd.$85.3M0.97%$11.35$35.13+209.5%
1.0%
REPLReplimune Group, Inc.$80.5M0.92%$8.67$11.58+33.6%
0.9%
TRDAEntrada Therapeutics, Inc.$73.4M0.84%$15.17$7.72-49.1%
0.8%
RAREUltragenyx Pharmaceutical Inc.$70.1M0.80%$48.17$33.47-30.5%
0.8%
CERECerevel Therapeutics Holdings, Inc.$67.8M0.77%β€”β€”
0.8%
IMTXImmatics N.V.$61.5M0.70%$10.72$9.95-7.2%
0.7%
BCRXBioCryst Pharmaceuticals, Inc.$60.7M0.69%$6.07$9.84+62.1%
0.7%
ARGXargenx SE$57.5M0.65%$381.00$939.68+146.6%
0.7%
DNLIDenali Therapeutics Inc.$56.0M0.64%$21.39$25.83+20.8%
0.6%
AKROAkero Therapeutics, Inc.$55.3M0.63%β€”β€”
0.6%
KODKodiak Sciences Inc.$52.6M0.60%$3.18$38.54+1112.0%
0.6%
KNSAKiniksa Pharmaceuticals, Ltd.$49.3M0.56%$18.53$64.53+248.3%
0.6%
XENEXenon Pharmaceuticals Inc.$45.8M0.52%$44.91$60.96+35.7%
0.5%
PRLDPrelude Therapeutics Inc.$43.2M0.49%$4.07$4.91+20.6%
0.5%
CERSCerus Corporation$42.1M0.48%$2.16$3.16+46.3%
0.5%
NRIXNurix Therapeutics, Inc.$40.1M0.46%$10.22$23.97+134.5%
0.5%
AVTEAerovate Therapeutics, Inc.$38.0M0.43%β€”β€”
0.4%
IDYAIDEAYA Biosciences, Inc.$37.8M0.43%$35.22$37.65+6.9%
0.4%
EWTXEdgewise Therapeutics, Inc.$34.0M0.39%$11.00$39.56+259.6%
0.4%

Quarter-on-Quarter Activity

Q4 2023 vs. Q3 2023

New Positions (5)

TickerIssuerNotional
CERECerevel Therapeutics Holdings, Inc.$67.8M
CLDXCelldex Therapeutics, Inc.$9.8M
NGNENeurogene Inc.$8.8M
PFEPfizer Inc.$1.0M
TYRATyra Biosciences, Inc.$0.1M

Exited Positions (8)

TickerIssuerNotional
SGENSeagen Inc.$9.45B
BMRNBioMarin Pharmaceutical Inc.$337.1M
SWTXSpringWorks Therapeutics, Inc.$69.4M
COGTCogent Biosciences, Inc.$12.6M
PACBPacific Biosciences of California, Inc.$9.4M
HRTXHeron Therapeutics, Inc.$8.4M
ARVNArvinas, Inc.$8.1M
BLUEXXXXbluebird bio, Inc.$7.6M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
SERASera Prognostics, Inc.$29.7M+258.6%
EWTXEdgewise Therapeutics, Inc.$28.0M+196.5%+259.6%
MRTXMirati Therapeutics, Inc.$180.7M+192.3%
BCYCBicycle Therapeutics plc$15.4M+112.2%
REPLReplimune Group, Inc.$2.1M+108.5%+33.6%
GRCLGracell Biotechnologies Inc.$18.0M+108.0%
XNCRXencor, Inc.$2.7M+99.3%
RVMDRevolution Medicines, Inc.$73.2M+91.3%+570.4%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
CABACabaletta Bio, Inc.$-24.0M-99.2%
PRAXPraxis Precision Medicines, Inc.$-0.3M-93.0%
WHWKAadi Bioscience, Inc.$-4.3M-74.6%
BCELAtreca, Inc.$-0.6M-38.4%
ROIVRoivant Sciences Ltd.$-53.5M-36.1%+209.5%
IPSCCentury Therapeutics, Inc.$0.3M-30.6%
BCRXBioCryst Pharmaceuticals, Inc.$-29.3M-20.3%+62.1%
ACHLAchilles Therapeutics plc$-0.5M-17.8%
← Back to Hedge Funds
Baker Bros Advisors Q4 2023 13F Filing β€” Holdings & Portfolio | MarketsFN